Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally.
+ 2 more risks
Alimera Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.82|
|52 Week High||US$3.82|
|52 Week Low||US$12.25|
|1 Month Change||-12.36%|
|3 Month Change||-49.26%|
|1 Year Change||-14.08%|
|3 Year Change||-70.25%|
|5 Year Change||-80.29%|
|Change since IPO||-97.08%|
Recent News & Updates
Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...
|ALIM||US Pharmaceuticals||US Market|
Return vs Industry: ALIM underperformed the US Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: ALIM underperformed the US Market which returned 33.7% over the past year.
Stable Share Price: ALIM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ALIM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors.
Is Alimera Sciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALIM ($4.82) is trading below our estimate of fair value ($18.23)
Significantly Below Fair Value: ALIM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALIM is good value based on its PE Ratio (16.5x) compared to the US Pharmaceuticals industry average (24.4x).
PE vs Market: ALIM is good value based on its PE Ratio (16.5x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: ALIM's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ALIM has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is Alimera Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALIM's earnings are forecast to decline over the next 3 years (-77.6% per year).
Earnings vs Market: ALIM's earnings are forecast to decline over the next 3 years (-77.6% per year).
High Growth Earnings: ALIM's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ALIM's revenue (9.2% per year) is forecast to grow slower than the US market (9.7% per year).
High Growth Revenue: ALIM's revenue (9.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALIM's Return on Equity is forecast to be high in 3 years time
How has Alimera Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALIM has a large one-off gain of $2.2M impacting its June 30 2021 financial results.
Growing Profit Margin: ALIM became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ALIM has become profitable over the past 5 years, growing earnings by 39.4% per year.
Accelerating Growth: ALIM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALIM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: Whilst ALIM's Return on Equity (39.42%) is high, this metric is skewed due to their high level of debt.
How is Alimera Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: ALIM's short term assets ($45.2M) exceed its short term liabilities ($10.3M).
Long Term Liabilities: ALIM's short term assets ($45.2M) do not cover its long term liabilities ($45.9M).
Debt to Equity History and Analysis
Debt Level: ALIM's debt to equity ratio (723.1%) is considered high.
Reducing Debt: ALIM's debt to equity ratio has increased from 281.7% to 723.1% over the past 5 years.
Debt Coverage: ALIM's debt is not well covered by operating cash flow (4.2%).
Interest Coverage: ALIM's interest payments on its debt are not well covered by EBIT (0.9x coverage).
What is Alimera Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALIM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALIM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALIM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALIM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Eiswirth (53 yo)
Mr. Richard S. Eiswirth, Jr., also known as Rick, has been President of Alimera Sciences, Inc. since January 1, 2016 and its Chief Executive Officer and Director since January 2, 2019. He was Chief Financi...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD887.86K) is above average for companies of similar size in the US market ($USD548.10K).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
Experienced Management: ALIM's management team is considered experienced (2.7 years average tenure).
Experienced Board: ALIM's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.6%.
Alimera Sciences, Inc.'s employee growth, exchange listings and data sources
- Name: Alimera Sciences, Inc.
- Ticker: ALIM
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$33.375m
- Shares outstanding: 6.92m
- Website: https://www.alimerasciences.com
Number of Employees
- Alimera Sciences, Inc.
- 6120 Windward Parkway
- Suite 290
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 22:53|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.